AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

Calendar

Sep. 30 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change
26-08-31	€0.7170	-1.10%
26-08-28	€0.7250	+2.40%
26-08-27	€0.7080	-3.28%
26-08-26	€0.7320	+9.91%
26-08-25	€0.6660	-2.77%

Delayed Quote Deutsche Boerse AG

More quotes

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Deutsche Boerse AG 02:09:54 2026-08-31 am EDT			5-day change	1st Jan Change
0.7170 ^EUR	-1.10%		+4.67%	-47.43%

Aug. 17	AB Science completes settlement and delivery of its private placement
Aug. 10	AB Science Wraps Up EUR14 Million Private Placements	MT

Market Cap	56.25M 65.33M 52.82M 48.21M 90.57M 6.22B 91.22M 626M 244M 3.15B 245M 240M 10.44B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	56.25M 65.33M 52.82M 48.21M 90.57M 6.22B 91.22M 626M 244M 3.15B 245M 240M 10.44B	EV / Sales 2026 *	46.9x	EV / Sales 2027 *	43.3x
Free-Float	69.03%	Yield 2026 *	-	Yield 2027 *	-

Aug. 17	AB Science completes settlement and delivery of its private placement
Aug. 10	AB Science Wraps Up EUR14 Million Private Placements	MT
Aug. 10	AB Science raises €14.2m
Jul. 13	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
Jul. 10	AB Science streamlines its portfolio and refocuses on two molecules
Jul. 10	AB Science SA Provides Update on Clinical Program, Suspends Non-Priority Clinical Trials and Focuses on Ab8939 and Masitinib Programs	CI
Jul. 08	Stéphane Ledermann takes the helm at AB Science as CEO
Jul. 06	AB Science S.A. Announces Board Changes	CI
Jul. 06	AB Science S.A. Announces CEO Changes	CI
Jul. 02	AB Science S.A. announced that it has received $2.01616 million in funding	CI
Jul. 01	AB Science, successful private placement
Jun. 30	AB Science S.A. announced that it has received ?2.294 million in funding	CI
Jun. 29	AB Science Reports Completion of Step 3 of Phase 1 Evaluating Combination of Ab8939 with Venetoclax for Treatment of Refractory or Relapsed Acute Myeloid Leukemia	CI

Aug. 17	AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 2026	GL
Aug. 10	AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million	GL
Aug. 04	AB Science : Webconference presentation on masitinib + isoquercetin in COVID-19	PU
Jul. 10	AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs	GL
Jul. 08	AB Science : Board of Directors is restructuring its governance to usher in a new phase in the company’s development	PU

AB Science Stock Deutsche Boerse AG

Stocks

A8D

FR0010557264

Pharmaceuticals

Valuation : AB Science

Chart: AB Science

Latest news : AB Science

Last Transcript : AB Science

Press Releases : AB Science

News in other languages : AB Science

Quotes and Performance

Price Extremes

Managers and Directors : AB Science

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

Aug. 24	AB Science : Franchissement de seuils et déclaration d'intention
Aug. 17	Bourse : Stellantis s'agite, ArgenX communique et PayPal fait monter les enchères
Aug. 17	AB Science procède au règlement-livraison de son placement privé
Aug. 17	AB Science : annonce le succès du règlement-livraison des titres émis dans le cadre de son placement privé de 14,2 millions d’euros annoncé le 10 aout 2026
Aug. 17	AB Science annonce le succès du règlement-livraison des titres émis dans le cadre de son placement privé de 14,2 millions d’euros annoncé le 10 aout 2026

1 day	-1.10%
1 week	+4.67%
Current month	+34.52%
1 month	+34.52%
3 months	-24.68%
6 months	-44.42%
Current year	-47.43%

1 week	0.67	0.73
1 month	0.54	0.98
Current year	0.52	1.55
1 year	0.52	1.55
3 years	0.52	3.88
5 years	0.52	14.53
10 years	0.52	20.1

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	2026-07-06
Laurent Guy DFI	Director of Finance/CFO	-	2009-11-19
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	2018-03-31

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	2001-07-10
Patrick Moussy BRD	Director/Board Member	-	2011-09-19
Cécile de Guillebon BRD	Director/Board Member	65	2021-06-26

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	-1.10%	+4.67%	-	-	67.14M
MERCK & CO., INC.	-0.40%	-3.14%	+75.65%	+34.07%	366B
MERCK KGAA	-0.89%	+0.43%	+27.87%	-16.27%	70.76B
HALOZYME THERAPEUTICS, INC.	+1.08%	-1.98%	+45.20%	+150.21%	11.96B
KYOWA KIRIN CO., LTD.	-1.33%	+2.00%	+3.26%	-1.02%	8.72B
SK BIOPHARMACEUTICALS CO., LTD.	-0.80%	+4.30%	-11.46%	+0.92%	5B
YUHAN CORPORATION	-1.41%	+1.70%	-26.26%	+21.05%	4.59B
BETTA PHARMACEUTICALS CO., LTD.	-0.14%	-1.37%	-28.57%	+2.92%	3.16B
SUPERNUS PHARMACEUTICALS, INC.	+1.10%	-2.00%	-0.74%	+38.85%	2.54B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-2.27%	-3.75%	-17.97%	-14.26%	2.08B
Average	-0.62%	-0.19%	+7.44%	+24.05%	52.76B
Weighted average by Cap.	-0.47%	-1.86%	+63.02%	+27.98%

	2026 *	2027 *
Net sales	1.2M 1.39M 1.13M 1.03M 1.93M 133M 1.95M 13.35M 5.19M 67.25M 5.23M 5.12M 223M	1.3M 1.51M 1.22M 1.11M 2.09M 144M 2.11M 14.46M 5.63M 72.85M 5.67M 5.55M 241M
Net income	-	-
Net Debt	-	-